更新关于用于骨关节炎治疗的甲福明的最新情况
Ben-Zheng Li1,2, He-Xin Wei1,2, Shu-Zhi Li1,2
1First Clinical Medical College of Gansu, University of Traditional Chinese Medicine, Lanzhou, China.
Inflammopharmacology
|September 25, 2025
概括
甲胺通过利用其抗炎症和代谢功效显示出治疗关节骨炎 (OA) 的前景. 本综述探讨了它在管理这种常见的退行性关节疾病方面的潜力.
科学领域:
- 类风湿病学 类风湿病学
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 骨关节炎 (OA) 是一种广泛的退行性关节疾病,影响中年和老年人群.
- 代谢综合征 (Met S),其特点是代谢失调,经常包括肥胖,越来越多地与OA有关.
- 一种糖尿病药物梅特福尔因其抗炎和代谢性质而被研究OA.
研究的目的:
- 审查当前关于甲福明在治疗骨关节炎中的疗效的研究.
- 分析梅特福林对OA的影响背后的机制.
- 评估甲福尔明在OA管理中的临床潜力.
主要方法:
- 对最近对甲福明和OA进行的临床和动物研究的系统审查.
- 对甲福明的抗炎,抗氧化和代谢机制的分析与OA相关.
- 评估现有关于甲福尔明在OA治疗潜力的数据.
主要成果:
- 甲福明表现出抗炎,抗氧化和代谢调节性质.
- 新出现的证据表明,甲双可能会对OA的进展和症状产生积极的影响.
- 需要进一步的研究才能充分阐明它在关节炎治疗中的作用.
结论:
- 甲胺为骨关节炎提供了潜在的治疗选择,特别是在有代谢并发症的患者中.
- 它的多方面的机制为开放许可管理提供了一种新的方法.
- 需要进行临床试验来证实OA患者的疗效和安全性.
相关概念视频
Oral Hypoglycemic Agents: Biguanides and Glitazones
585
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
585
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
525
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
525
Oral Hypoglycemic Agents: Glinides
600
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
600
Oral Hypoglycemic Agents: Sulfonylureas
781
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
781
Diabetes: Management and Pharmacotherapy
868
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
868
Drug Dosing: Obese Patients
225
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
225


